Screener
Arbutus Biopharma Corporation ABUS Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| General and administrative | 5,889 | 5,832 |
| Change in fair value of contingent consideration | 209 | 299 |
| Restructuring costs | — | 12,373 |
| Total operating expenses | 10,218 | 27,463 |
| Income (loss) from operations | 168,908 | (25,699) |
| Other income | ||
| Interest income | 815 | 1,197 |
| Interest expense | (17) | (28) |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's other operating expenses?
- Arbutus Biopharma Corporation (ABUS) reported other operating expenses of $10.22M in Q1 2026.
- How has Arbutus Biopharma Corporation's other operating expenses changed year-over-year?
- Arbutus Biopharma Corporation's other operating expenses decreased by 62.8% year-over-year, from $27.46M to $10.22M.
- What is the long-term trend for Arbutus Biopharma Corporation's other operating expenses?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's other operating expenses has grown at a -11.3% compound annual growth rate (CAGR), from $84.51M to $52.24M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Arbutus Biopharma Corporation's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude